Literature DB >> 21039612

Gentamicin-attenuated Leishmania infantum: cellular immunity production and protection of dogs against experimental canine leishmaniasis.

H Daneshvar1, M M Molaei, H Kamiabi, R Burchmore, P Hagan, R Stephen Phillips.   

Abstract

An attenuated line of Leishmania infantum (L. infantum H-line) has been established by culturing promastigotes in vitro under gentamicin pressure. Here, we show that L. infantum H-line induced significantly higher levels of IFN-γ and lower levels of IL-10 compared with those in dogs infected with L. infantum wild type (WT). Anti-Leishmania-specific total IgG, IgG1, and IgG2 antibodies were present in the serum of all infected dogs, with levels of IgG2 subclass highest in the sera of dogs inoculated with L. infantum H-line. Relatively high levels of IgG1 were found in the sera of dogs infected with L. infantum WT. Six of seven dogs immunized intradermally (i.d.) with the attenuated line later showed a positive skin test to leishmanin, whereas the dogs infected with L. infantum WT did not. No clinical abnormalities were observed, and no parasites found in the visceral organs of the dogs inoculated intravenously (i.v.) with L. infantum H-line over 24 months post-inoculation. Dogs which had been immunized with L. infantum H-line i.d. 12 months previously were protected against challenge with L. infantum WT. These data suggest that the L. infantum H-line was safe and induced a protection which is correlated with cellular immunity in dogs.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21039612     DOI: 10.1111/j.1365-3024.2010.01237.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  11 in total

1.  Delta-aminolevulinate-induced host-parasite porphyric disparity for selective photolysis of transgenic Leishmania in the phagolysosomes of mononuclear phagocytes: a potential novel platform for vaccine delivery.

Authors:  Sujoy Dutta; Celia Chang; Bala Krishna Kolli; Shigeru Sassa; Malik Yousef; Michael Showe; Louise Showe; Kwang-Poo Chang
Journal:  Eukaryot Cell       Date:  2012-02-03

2.  Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis.

Authors:  William R Ravis; Alejandro Llanos-Cuentas; Nestor Sosa; Mara Kreishman-Deitrick; Karen M Kopydlowski; Carl Nielsen; Kirsten S Smith; Philip L Smith; Janet H Ransom; Yuh-Jing Lin; Max Grogl
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

3.  Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama.

Authors:  Néstor Sosa; Zeuz Capitán; Javier Nieto; Melissa Nieto; José Calzada; Hector Paz; Carmenza Spadafora; Mara Kreishman-Deitrick; Karen Kopydlowski; Diane Ullman; William F McCarthy; Janet Ransom; Jonathan Berman; Charles Scott; Max Grogl
Journal:  Am J Trop Med Hyg       Date:  2013-07-15       Impact factor: 2.345

4.  Development of Vaccines against Visceral Leishmaniasis.

Authors:  Krystal J Evans; Lukasz Kedzierski
Journal:  J Trop Med       Date:  2011-09-05

5.  Adjuvants for Leishmania vaccines: from models to clinical application.

Authors:  Vanitha S Raman; Malcolm S Duthie; Christopher B Fox; Greg Matlashewski; Steven G Reed
Journal:  Front Immunol       Date:  2012-06-11       Impact factor: 7.561

6.  Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.

Authors:  Mehdi Shahbazi; Farnaz Zahedifard; Tahereh Taheri; Yasaman Taslimi; Shahram Jamshidi; Sadegh Shirian; Niousha Mahdavi; Mehdi Hassankhani; Yahya Daneshbod; Sayyed Hamid Zarkesh-Esfahani; Barbara Papadopoulou; Sima Rafati
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

7.  Development of Leishmania vaccines: predicting the future from past and present experience.

Authors:  Joshua Muli Mutiso; John Chege Macharia; Maria Ndunge Kiio; James Maina Ichagichu; Hitler Rikoi; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-09-30

Review 8.  Live vaccination tactics: possible approaches for controlling visceral leishmaniasis.

Authors:  Noushin Saljoughian; Tahareh Taheri; Sima Rafati
Journal:  Front Immunol       Date:  2014-03-31       Impact factor: 7.561

9.  Gentamicin-attenuated Leishmania infantum vaccine: protection of dogs against canine visceral leishmaniosis in endemic area of southeast of Iran.

Authors:  Hamid Daneshvar; Mohammad Javad Namazi; Hossein Kamiabi; Richard Burchmore; Sarah Cleaveland; Stephen Phillips
Journal:  PLoS Negl Trop Dis       Date:  2014-04-17

10.  A dual drug sensitive L. major induces protection without lesion in C57BL/6 mice.

Authors:  Noushin Davoudi; Ali Khamesipour; Fereidoun Mahboudi; W Robert McMaster
Journal:  PLoS Negl Trop Dis       Date:  2014-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.